Navigation Links
Novalung Records 50% Growth
Date:3/23/2010

ANN ARBOR, Mich., March 23 /PRNewswire/ -- The innovative therapies for lung failure from medical device company Novalung GmbH continue to gain acceptance.  Additional financing will allow the Talheim (Germany) based company to accelerate the development of new products.

Novalung GmbH increased sales by 50% in 2009.  The increasing acceptance of the company's innovative therapies for lung failure both in Germany and abroad is driving continuing growth. Manufacturing operations moved into a new, larger clean-room facility at the end of 2009.

In order to maintain this growth and to fund further international expansion, the private equity group Zukunftsfonds Heilbronn GmbH & Co.KG ("Future Fund of Heilbronn", zfhn) and the LBank, state bank of Baden-Wurttemberg, completed an additional financing round for Novalung. The zfhn acted as lead investor for the second time.

Thanks to the additional funding, commercialization of new products can be pursued more aggressively. These measures put Novalung in an excellent position to establish itself internationally as the pioneering provider of solutions for lung failure, and to revolutionize the treatment of lung failure with new therapies.

Novalung products allow a paradigm shift from the mechanically ventilated patient in an artificial coma to the awake, mobile patient breathing spontaneously. The innovative technologies to replace mechanical ventilation and eliminate the associated ventilator-induced lung injury advance this approach and provide physicians, nurses and patients with new therapeutic options.

Novalung's vision for the future for the long-term treatment of patients with advanced lung disease is a small, wearable artificial lung that frees patients from respiratory stress, improves their overall condition and thus improves their quality of life.

Founded in 2003, Novalung GmbH operates on a highly international level in order to establish new solutions for lung failure. These advanced technologies from Germany and the U.S. were brought into the company and developed further.  Novalung's devices have been used to treat more than 5,000 patients.

The privately funded Novalung GmbH is a fast growing medical technology company based in the area of Heilbronn, Germany, with a subsidiary in Ann Arbor, Michigan.

Novalung has received limited FDA clearance to market its devices in the U.S., and the company plans to begin clinical trials here in 2010 to expand its indications in extracorporeal lung support.

SOURCE Novalung, Inc.

Back to top

RELATED LINKS
http://www.novalung.com

'/>"/>

SOURCE Novalung, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Praxis Electronic Medical Records Announces New Version 5 With Breakthrough in EHR Documentation
2. Aprima and MednetwoRx Partner to Provide Electronic Health Records and Remote Hosting Option to Physician Practices
3. Vicus Therapeutics Records Last Patient Visit of Phase 2, VT-122 Trial for the Treatment of Cachexia in Patients With Advanced Lung Cancer
4. Kensey Nash To Participate in the Sidoti Fourteenth Annual New York Emerging Growth Institutional Investor Forum
5. NOVAVAX to Present at 22nd Annual ROTH OC Growth Stock Conference
6. Vermillion to Present at the Roth 22nd Annual OC Growth Stock Conference March 15 - 17, Laguna Niguel, CA
7. Keryx Biopharmaceuticals to Present at the 22nd Annual ROTH OC Growth Stock Conference
8. Anadys Pharmaceuticals to Present at the ROTH OC Growth Stock Conference
9. International Growth Continues: Rhythmlink International, LLC Receives CE Marking & ISO 13485 Certification
10. DUSA Pharmaceuticals to Present at Roth Capital Partners 22nd Annual OC Growth Stock Conference
11. Acuo Technologies Announces Another Significant Sales and Implementation Growth Year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... April 29, 2016 ... Financier Sanofi, leader mondial ... ses résultats pour le premier trimestre ... Jérôme Contamine, commente les résultats du ... perspectives pour le reste de l,année. ...
(Date:4/28/2016)... , April 28, 2016  While Abbott,s announced ... the company,s valve repair and stent business, healthcare ... places Abbott more firmly into patient monitoring.  Kalorama ... fastest growing device areas, with double-digit growth expected ... report,  Advanced Remote Patient Monitoring . ...
(Date:4/28/2016)... -- The blood testing market in China ... and The Freedonia Group in a recent report.  The ... healthcare research firm said that China ... and in improving testing at the provincial level.   The ... Blood Testing Market in China , which utilized ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... 29, 2016 , ... In an article published April 16th on ... Botox and lip injections, which she underwent in order to feel more at home ... Arts Festival. The article explains that Ms. Mirmelli’s situation is not unique; many plastic ...
(Date:4/29/2016)... , ... April 29, 2016 , ... On Tuesday, April ... across the Southeast, celebrated the signature of Gov. Nathan Deal on SB 258, the ... Duncan (R - Cumming), offers a 70% tax credit to individuals and corporations which ...
(Date:4/29/2016)... , ... April 29, 2016 , ... Coast Dental Fort ... 2016, at its new location in the Exchange Furniture Mall at 112 Vilseck Road ... a 50-inch Samsung Smart TV. Plus attendees will have the opportunity to meet general ...
(Date:4/29/2016)... , ... April 29, 2016 , ... ... of patented products, announces the Gyrociser, an exercise invention which aids in proper ... billion," says Scott Cooper, CEO and Creative Director of World Patent Marketing. "Globalization ...
(Date:4/29/2016)... ... April 29, 2016 , ... Reltok Nasal Products proudly announces that Boston ... and neck/ear, nose and throat specialty, has added the KOTLER NASAL AIRWAY™ to its ... is a newly patented safety device secured by nasal surgeons onto the floor ...
Breaking Medicine News(10 mins):